• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抗炎性2-芳基丙酸类(丙酸类药物)与脂肪酸代谢的相互作用:体外研究

Interactions of anti-inflammatory 2-arylpropionates (profens) with the metabolism of fatty acids: in vitro studies.

作者信息

Mayer J M, Roy-De Vos M, Audergon C, Testa B, Etter J C

机构信息

School of Pharmacy, University of Lausanne, Switzerland.

出版信息

Int J Tissue React. 1994;16(2):59-72.

PMID:7960502
Abstract

This review shows conclusively that profens can enter physiological pathways of lipid biochemistry. The first step in this interaction is the formation of an acyl-CoA thioester. These conjugates can lead to the incorporation of the xenobiotic acid into lipids. The resulting hybrid triglycerides have the potential to form long-lasting residues in adipose tissues and to be incorporated into membranes. Furthermore, the acyl-CoA conjugate may also alter lipid biochemistry by inhibiting lipid beta-oxidation either by interfering with the acyl-CoA synthetases or by modifying CoA levels. Thus, the acyl-CoA conjugates of profens intermediates in the inversion of inactive (R)-profens to active (S)-profens can be viewed as pivotal to bioactivation and to pathways of potential toxicity.

摘要

本综述确凿地表明,丙酸类药物可进入脂质生物化学的生理途径。这种相互作用的第一步是形成酰基辅酶A硫酯。这些共轭物可导致外源性酸掺入脂质中。由此产生的杂合甘油三酯有可能在脂肪组织中形成持久的残留物并掺入细胞膜。此外,酰基辅酶A共轭物还可能通过干扰酰基辅酶A合成酶或改变辅酶A水平来抑制脂质β-氧化,从而改变脂质生物化学。因此,丙酸类药物中间体的酰基辅酶A共轭物在无活性(R)-丙酸类药物转化为活性(S)-丙酸类药物的过程中,可被视为生物活化和潜在毒性途径的关键因素。

相似文献

1
Interactions of anti-inflammatory 2-arylpropionates (profens) with the metabolism of fatty acids: in vitro studies.抗炎性2-芳基丙酸类(丙酸类药物)与脂肪酸代谢的相互作用:体外研究
Int J Tissue React. 1994;16(2):59-72.
2
Stereoselective metabolism of anti-inflammatory 2-arylpropionates.抗炎2-芳基丙酸酯的立体选择性代谢
Acta Pharm Nord. 1990;2(3):197-216.
3
Ibuprofen enantiomers and lipid metabolism.布洛芬对映体与脂质代谢。
J Clin Pharmacol. 1996 Dec;36(12 Suppl):27S-32S.
4
Pharmacodynamics and pharmacokinetics of the profens: enantioselectivity, clinical implications, and special reference to S(+)-ibuprofen.丙酸类药物的药效学和药代动力学:对映体选择性、临床意义及对S(+)-布洛芬的特别参考
J Clin Pharmacol. 1996 Dec;36(12 Suppl):7S-15S.
5
Enantioselective formation of ibuprofen-S-acyl-glutathione in vitro in incubations of ibuprofen with rat hepatocytes.布洛芬与大鼠肝细胞孵育时在体外对映选择性形成布洛芬 - S - 酰基谷胱甘肽。
Chem Res Toxicol. 2008 Sep;21(9):1749-59. doi: 10.1021/tx800098h. Epub 2008 Aug 5.
6
Increased malonyl-CoA levels in muscle from obese and type 2 diabetic subjects lead to decreased fatty acid oxidation and increased lipogenesis; thiazolidinedione treatment reverses these defects.肥胖和2型糖尿病患者肌肉中丙二酰辅酶A水平升高会导致脂肪酸氧化减少和脂肪生成增加;噻唑烷二酮治疗可逆转这些缺陷。
Diabetes. 2006 Aug;55(8):2277-85. doi: 10.2337/db06-0062.
7
Identification of a potential bottleneck in branched chain fatty acid incorporation into triacylglycerol for lipid biosynthesis in agronomic plants.鉴定农艺植物中支链脂肪酸掺入三酰甘油用于脂质生物合成过程中的一个潜在瓶颈。
Biochimie. 2009 Jun;91(6):703-10. doi: 10.1016/j.biochi.2009.03.011. Epub 2009 Mar 26.
8
Acyl-coenzyme A binding protein expression alters liver fatty acyl-coenzyme A metabolism.酰基辅酶A结合蛋白的表达改变肝脏脂肪酸辅酶A代谢。
Biochemistry. 2005 Aug 2;44(30):10282-97. doi: 10.1021/bi0477891.
9
Novel functions of acyl-CoA thioesterases and acyltransferases as auxiliary enzymes in peroxisomal lipid metabolism.酰基辅酶A硫酯酶和酰基转移酶作为过氧化物酶体脂质代谢辅助酶的新功能。
Prog Lipid Res. 2008 Nov;47(6):405-21. doi: 10.1016/j.plipres.2008.05.001. Epub 2008 May 15.
10
New insights in peroxisomal beta-oxidation. Implications for human peroxisomal disorders.过氧化物酶体β-氧化的新见解。对人类过氧化物酶体疾病的影响。
Verh K Acad Geneeskd Belg. 1998;60(3):195-214.

引用本文的文献

1
Chiral inversion of (R)-ketoprofen: influence of age and differing physiological status in dairy cattle.(R)-酮洛芬的手性反转:奶牛年龄及不同生理状态的影响
Vet Res Commun. 2002 Jan;26(1):29-37. doi: 10.1023/a:1013301620904.
2
Clinical pharmacokinetics of dexketoprofen.右酮洛芬的临床药代动力学
Clin Pharmacokinet. 2001;40(4):245-62. doi: 10.2165/00003088-200140040-00002.
3
Preclinical and clinical development of dexketoprofen.右酮洛芬的临床前及临床开发
Drugs. 1996;52 Suppl 5:24-45; discussion 45-6. doi: 10.2165/00003495-199600525-00005.
4
Comparison of the bioavailability of dexibuprofen administered alone or as part of racemic ibuprofen.
Eur J Clin Pharmacol. 1995;48(6):505-11. doi: 10.1007/BF00194342.